Stock listing
NASDAQ:TTRX Turn Therapeutics Inc. Stock
Home listing (NASDAQ) of Turn Therapeutics Inc.
Follow Turn Therapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TTRX
$8.10 USD -0.79 (-8.9%)
Close on Nov 20, 2026
- Day range
- $7.93 – $9.20 USDNov 20, 2026
- Volume
- 82,671 sharesNov 20, 2026
- Market cap
- $247.5M USDAt the close on Nov 20, 2026 · price × 30.57M shares outstanding
- 52-week range
- $2.60 – $16.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.39M USDMedian day 96,205 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TTRX · Home | $8.095 USD | -0.795 (-8.9%) | 82,671 | $8.85 | $9.20 | $7.93 | $8.89 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TTRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.095 | -0.795 | -8.9% | $8.85 | $9.20 | $7.93 | 82,671 | |
| $8.89 | +0.34 | +4.0% | $8.19 | $9.43 | $8.19 | 52,416 | |
| $8.55 | 0.00 | 0.0% | $8.75 | $9.105 | $8.09 | 126,358 | |
| $8.55 | -0.795 | -8.5% | $9.20 | $9.635 | $8.20 | 148,595 | |
| $9.345 | -0.785 | -7.7% | $10.25 | $10.28 | $9.28 | 92,172 | |
| $10.13 | -0.44 | -4.2% | $10.49 | $10.50 | $9.995 | 98,771 | |
| $10.57 | +0.65 | +6.6% | $10.11 | $11.18 | $10.11 | 56,969 | |
| $9.92 | +0.13 | +1.3% | $9.72 | $10.22 | $9.52 | 88,089 | |
| $9.79 | +0.31 | +3.3% | $8.795 | $9.855 | $8.45 | 135,954 | |
| $9.48 | +0.54 | +6.0% | $9.13 | $9.69 | $8.78 | 98,132 | |
| $8.94 | -0.86 | -8.8% | $9.66 | $10.19 | $8.30 | 133,059 | |
| $9.80 | +0.29 | +3.0% | $9.77 | $10.11 | $9.645 | 93,967 | |
| $9.51 | -0.14 | -1.5% | $9.65 | $10.33 | $9.455 | 118,255 | |
| $9.65 | -0.78 | -7.5% | $10.48 | $10.48 | $9.65 | 85,806 | |
| $10.43 | -0.29 | -2.7% | $10.45 | $10.54 | $9.60 | 136,825 | |
| $10.72 | -0.40 | -3.6% | $10.86 | $11.31 | $10.65 | 137,690 | |
| $11.12 | +0.70 | +6.7% | $10.48 | $11.55 | $10.28 | 48,801 | |
| $10.42 | -0.19 | -1.8% | $10.49 | $10.83 | $10.10 | 98,414 | |
| $10.61 | +0.33 | +3.2% | $10.16 | $10.82 | $10.04 | 96,205 | |
| $10.28 | +0.10 | +1.0% | $10.59 | $10.79 | $10.09 | 87,000 | |
| $10.18 | +0.03 | +0.3% | $10.05 | $10.47 | $9.83 | 113,100 | |
| $10.15 | -0.32 | -3.1% | $10.61 | $10.72 | $10.14 | 60,600 | |
| $10.47 | -0.27 | -2.5% | $10.54 | $10.74 | $10.28 | 76,900 | |
| $10.74 | +0.17 | +1.6% | $10.72 | $10.87 | $10.60 | 29,900 | |
| $10.57 | -1.02 | -8.8% | $11.49 | $11.49 | $10.39 | 105,600 | |
| $11.59 | +0.48 | +4.3% | $10.85 | $11.89 | $10.85 | 80,300 | |
| $11.11 | +0.51 | +4.8% | $10.42 | $11.44 | $10.42 | 53,400 | |
| $10.60 | -0.51 | -4.6% | $11.12 | $11.40 | $10.26 | 117,400 | |
| $11.11 | -0.89 | -7.4% | $11.72 | $11.99 | $11.03 | 45,900 | |
| $12.00 | +0.61 | +5.4% | $11.34 | $12.00 | $11.30 | 109,800 | |
| $11.39 | -0.71 | -5.9% | $11.94 | $12.00 | $11.24 | 110,100 | |
| $12.10 | +0.46 | +4.0% | $11.58 | $13.05 | $11.31 | 175,700 | |
| $11.64 | -0.72 | -5.8% | $12.35 | $12.42 | $11.57 | 74,800 | |
| $12.36 | -0.97 | -7.3% | $13.18 | $13.18 | $12.00 | 111,300 | |
| $13.33 | +0.02 | +0.2% | $13.35 | $13.48 | $12.17 | 136,300 | |
| $13.31 | -1.08 | -7.5% | $14.25 | $14.25 | $13.02 | 122,000 | |
| $14.39 | +0.98 | +7.3% | $13.41 | $14.63 | $13.02 | 88,700 | |
| $13.41 | +0.37 | +2.8% | $13.04 | $13.89 | $12.85 | 79,500 | |
| $13.04 | +0.55 | +4.4% | $12.29 | $13.13 | $12.29 | 76,700 | |
| $12.49 | -0.77 | -5.8% | $13.24 | $13.68 | $12.30 | 90,000 | |
| $13.26 | -0.25 | -1.9% | $13.50 | $13.88 | $12.07 | 244,900 | |
| $13.51 | -1.78 | -11.6% | $15.30 | $15.65 | $13.50 | 101,600 | |
| $15.29 | -0.05 | -0.3% | $15.31 | $15.44 | $14.53 | 122,500 | |
| $15.34 | +0.40 | +2.7% | $15.05 | $15.56 | $13.59 | 172,900 | |
| $14.94 | +1.12 | +8.1% | $13.80 | $16.45 | $13.80 | 929,900 | |
| $13.82 | +0.10 | +0.7% | $13.65 | $14.50 | $13.65 | 199,900 | |
| $13.72 | +0.26 | +1.9% | $13.46 | $14.21 | $13.40 | 150,300 | |
| $13.46 | +0.01 | +0.1% | $13.37 | $13.85 | $13.22 | 85,100 | |
| $13.45 | +0.76 | +6.0% | $12.43 | $13.82 | $12.11 | 131,500 | |
| $12.69 | -0.69 | -5.2% | $13.30 | $14.25 | $12.63 | 135,700 | |
| $13.38 | -0.37 | -2.7% | $13.34 | $14.29 | $13.03 | 125,100 | |
| $13.75 | +1.09 | +8.6% | $12.61 | $14.39 | $12.58 | 277,500 | |
| $12.66 | +2.86 | +29.2% | $9.99 | $12.68 | $9.82 | 320,500 | |
| $9.80 | -0.27 | -2.7% | $9.975 | $10.50 | $9.70 | 70,600 | |
| $10.07 | +0.40 | +4.1% | $9.67 | $10.50 | $9.67 | 82,500 | |
| $9.67 | -0.15 | -1.5% | $9.70 | $10.25 | $9.00 | 106,400 | |
| $9.82 | +0.22 | +2.3% | $9.60 | $10.29 | $9.28 | 43,200 | |
| $9.60 | -0.24 | -2.4% | $9.83 | $10.25 | $9.50 | 31,600 | |
| $9.84 | -0.27 | -2.7% | $10.10 | $10.28 | $9.47 | 62,800 | |
| $10.11 | +0.48 | +5.0% | $9.54 | $10.25 | $9.51 | 47,600 | |
| $9.63 | -0.10 | -1.0% | $10.04 | $10.04 | $9.45 | 69,200 | |
| $9.73 | +0.05 | +0.5% | $9.78 | $10.04 | $9.58 | 31,400 | |
| $9.68 | +0.22 | +2.3% | $9.39 | $9.87 | $9.04 | 70,300 | |
| $9.46 | -0.08 | -0.8% | $9.635 | $9.925 | $9.35 | 22,200 | |
| $9.54 | -0.28 | -2.9% | $9.945 | $10.03 | $9.52 | 32,000 |
- Ticker
- NASDAQ:TTRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London
Latest deck · Nov 10, 2026
Investor Presentation (November 2026)
Investor deck · 37 slides
Latest news
Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London
Nov 16, 2026
Closed $8.55 (-8.5%) on Nov 16, 2026
Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
Nov 9, 2026
Closed $9.79 (+3.3%) on Nov 9, 2026
Turn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program
Nov 5, 2026
Closed $8.94 (-8.8%) on Nov 5, 2026
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
Oct 21, 2026
Closed $10.18 (+0.3%) on Oct 22, 2026
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Sep 10, 2026
Closed $13.38 (-2.7%) on Sep 10, 2026
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
Sep 9, 2026
Closed $13.75 (+8.6%) on Sep 9, 2026
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
Aug 20, 2026
Closed $9.54 (-2.9%) on Aug 20, 2026
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
Aug 12, 2026
Closed $9.86 (-6.5%) on Aug 13, 2026
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
Jul 28, 2026
Closed $7.70 (-1.0%) on Jul 28, 2026
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Jul 7, 2026
Closed $9.71 (+26.3%) on Jul 7, 2026
Turn Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 31 in all · newest Nov 16, 2026 · oldest 2025
- Decks
- 8 decks · latest Nov 10, 2026
Where Turn Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TTRX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:TTRX | BOATS | United States | USD |
Valuation
Price/book 43.5× against a median of 1.2×: the highest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $244.2M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 43.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 1.1×
- Beta vs S&P 500
- 1.54
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Turn Therapeutics Inc. · NASDAQ:TTRX | US$247.5M | US$244.2M | n/a | n/a | n/a | 43.5× | n/a | 1.1× | 1.54 |
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| SAB Biotherapeutics, Inc. · NASDAQ:SABS | US$255.7M | US$156.5M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.19 |
| Evommune, Inc. · NYSE:EVMN | US$255.5M | US$86.86M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 0.96 |
| Editas Medicine, Inc. · NASDAQ:EDIT | US$253.1M | US$119.7M | n/a | 2.4× | n/a | 3.0× | −144.9% | 0.7× | 2.22 |
| Q32 Bio Inc. · NASDAQ:QTTB | US$249.6M | −US$35.66M | 7.7× | −0.7× | −1.9× | 0.9× | 59.8% | 0.0× | 0.59 |
| Mabpharm Limited · HKEX:2181 | US$247.3M | US$279.4M | 29.7× | 3.0× | 28.9× | 8.5× | 8.8% | 1.6× | n/a |
| Lexeo Therapeutics, Inc. · NASDAQ:LXEO | US$245.1M | US$56.52M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.62 |
| Shandong Boan Biotechnology Company., Limited. Class H · HKEX:6955 | US$242.7M | US$93.26M | 227× | 0.8× | 4.7× | 0.6× | 0.9% | 0.0× | n/a |
| Curocell, Inc. · KRX:372320 | US$241.3M | US$192.5M | n/a | n/a | n/a | 4.5× | n/a | 0.2× | n/a |
| Clinuvel Pharmaceuticals Limited · ASX:CUV | US$238.9M | US$73.38M | 10.3× | 1.1× | 2.6× | 1.3× | 36.0% | 0.0× | n/a |
| Median of the others | US$248.4M | US$90.06M | 20.0× | 1.1× | 3.6× | 1.2× | 8.8% | 0.0× | 1.41 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 25.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.46 · 2 analysts
- Revenue, year to Dec 2026
- 250K · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Bradley Burnam | Chief Executive Officer |
| Sasha Damouni | Investor Relations / Media Contact |
| Sasha Damouni Ellis | Corporate Communications & IR Lead |
| Zuraiz Chaudhary | Chief Accounting Officer, VP Finance |
| Muhammad Zubair | Controller |
| Neil Ghodadra | Chief Medical Officer, Board Director |
| Robert Redfield | Chief Scientific Officer |
| Stephen M. Hahn | Executive Clinical and Regulatory Lead |
Board
| Director | Role |
|---|---|
| Martin Dewhurst | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | +3.3% |
| Q2 2026 | Aug 12, 2026 · After close | −6.5% |
| Q1 2026 | May 11, 2026 · After close | +2.6% |
| Q4 2025 | Mar 31, 2026 · Before open | −0.6% |
| Q3 2025 | Nov 13, 2025 | −9.1% |
| Q2 2025 | Sep 16, 2025 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 37 slides | Nov 10, 2026 |
| Investor Presentation (October 2026) | Investor deck | 37 slides | Oct 7, 2026 |
| Investor Presentation (July 2026) | Investor deck | 38 slides | Jul 28, 2026 |
| Investor Presentation (July 2026) | Investor deck | 25 slides | Jul 7, 2026 |
| 2026 Jefferies Global Healthcare Conference | Conference | 28 slides | Jun 3, 2026 |
| Investor Presentation (February 2026) | Investor deck | 31 slides | Feb 9, 2026 |
| Investor Presentation (January 2026) | Investor deck | 27 slides | Jan 7, 2026 |
| Investor Presentation (September 2025) | Investor deck | 24 slides | September 2025 |
Financings
| Raise | Date |
|---|---|
| Shares under existing share purchase agreement Closed: raise Use of proceeds: Strengthen the balance sheet and extend operating runway into late 2026 for clinical and strategic objectives | Jan 12, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | |
| Cost of revenue | 52.7K | |||
| Gross profit | -52.7K | |||
| Research and development | 265.6K | 246.0K | 7.50K | |
| Selling, general and administrative | 5.59M | 1.55M | 2.30M | 4.21M |
| Operating income | -5.86M | -1.80M | -2.31M | -4.21M |
| Depreciation and amortization | 52.7K | 47.5K | 43.9K | 52.7K |
| EBITDA | -5.81M | -1.75M | -2.26M | -4.16M |
| Interest expense | 85.4K | |||
| Income before tax | -3.19M | -1.77M | -2.29M | -4.29M |
| Income tax | 800 | |||
| Net income | -3.19M | -1.77M | -2.29M | -4.29M |
| Earnings per share, basic | -0.12 | -0.07 | -0.17 | -0.33 |
| Earnings per share, diluted | -0.12 | -0.07 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 4.03M | 498.3K | 1.18M | 2.10M |
| Current assets | 5.20M | 1.10M | 1.20M | 2.13M |
| Total assets | 12.2M | 2.05M | 2.01M | 2.91M |
| Accounts payable | 2.93M | 256.0K | ||
| Current liabilities | 6.00M | 707.9K | 489.8K | 1.72M |
| Total debt | 80.4K | 121.0K | 25.2K | 83.7K |
| Total liabilities | 7.48M | 2.23M | 1.93M | 1.76M |
| Shareholders' equity | 4.69M | -177.4K | 85.8K | 1.16M |
| Shares outstanding | 29.4M | 26.8M | 13.2M | 13.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -2.56M | -1.36M | -1.38M | -1.24M |
| Capital spending | -153.0K | -99.5K | -44.3K | 0 |
| Free cash flow | -2.72M | -1.46M | -1.42M | -1.24M |
| Cash from investing | -153.0K | -99.5K | -44.3K | -17.7K |
| Cash from financing | 6.92M | 1.15M | 500.0K | 350.0K |
| Change in cash | 4.20M | -308.4K | -922.0K | 2.10M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Nov 17, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 17, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Nov 16, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Nov 16, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 10, 2026 | Current report | SEC |
| S-3 · Registration statement | Nov 9, 2026 | Offer document | SEC |
| S-3 · Registration statement | Nov 9, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Oct 19, 2026 | Annual report | SEC |
All 131 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| DEF 14A · Proxy statement | Oct 19, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 6, 2026 | Current report | SEC |
| 8-K · Current report | Sep 10, 2026 | Current report | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| D | Aug 26, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 18, 2026 | Financing | SEC |
| 8-K · Current report | Aug 17, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 8-K · Current report | Jul 28, 2026 | Current report | SEC |
| 8-K · Current report | Jul 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 8-K · Current report | May 27, 2026 | Current report | SEC |
| 8-K · Current report | May 19, 2026 | Current report | SEC |
| 8-K · Current report | May 18, 2026 | Current report | SEC |
| C-TR | May 12, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2026 | Results | SEC |
| 8-K · Current report | Mar 24, 2026 | Material contract | SEC |
| 8-K · Current report | Feb 17, 2026 | Current report | SEC |
| 8-K · Current report | Feb 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 8-K · Current report | Jan 7, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 17, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 17, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 8-K · Current report | Nov 4, 2025 | Current report | SEC |
| 8-K · Current report | Oct 30, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Oct 29, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 28, 2025 | Material contract | SEC |
| 4 · Change in ownership | Oct 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 22, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| S-1 · Registration statement | Oct 9, 2025 | Offer document | SEC |
| 424B4 · Prospectus | Oct 8, 2025 | Offer document | SEC |
| 3 · Initial statement of ownership | Oct 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 7, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Oct 7, 2025 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Oct 7, 2025 | Other filings | SEC |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Oct 7, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 2, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Oct 1, 2025 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Sep 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 24, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 24, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 23, 2025 | Other filings | SEC |
| 1-SA | Sep 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 16, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 16, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 11, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Sep 2, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 29, 2025 | Other filings | SEC |
| S-1 · Registration statement | Aug 29, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 14, 2025 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jul 30, 2025 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jul 30, 2025 | Offer document | SEC |
| 1-K | Jun 27, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Jun 20, 2025 | Offer document | SEC |
| 253G2 | Jun 13, 2025 | Other filings | SEC |
| C-AR | Apr 29, 2025 | Other filings | SEC |
| 253G2 | Apr 22, 2025 | Other filings | SEC |
| 253G2 | Apr 2, 2025 | Other filings | SEC |
| QUALIF | Apr 1, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2025 | Other filings | SEC |
| 1-A/A | Mar 27, 2025 | Other filings | SEC |
| 1-A/A | Mar 26, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 25, 2025 | Other filings | SEC |
| 1-A/A | Mar 25, 2025 | Other filings | SEC |
| C-U | Mar 24, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 18, 2025 | Other filings | SEC |
| 1-A/A | Mar 18, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 17, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 6, 2025 | Other filings | SEC |
| 1-A/A | Mar 6, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 27, 2025 | Other filings | SEC |
| 1-A | Jan 31, 2025 | Other filings | SEC |
| C/A | Jan 17, 2025 | Other filings | SEC |
| C/A | Dec 18, 2024 | Other filings | SEC |
| C-U | Nov 12, 2024 | Other filings | SEC |
| C | Oct 22, 2024 | Other filings | SEC |
| C/A | Aug 19, 2024 | Other filings | SEC |
| C/A | Jul 15, 2024 | Other filings | SEC |
| C | May 22, 2024 | Other filings | SEC |
Cap table
Built by 6ix from Turn Therapeutics Inc.’s releases · as of Nov 6, 2026
- Common shares
- 30,572,704
- Fully diluted
- 30,572,704
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 30,572,704 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 30,572,704 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Andrew Gengos Other companies: Immuneering Corporation (Chief Financial Officer and Treasurer · Since at least Jul 16, 2026); Terns Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Feb 24, 2025); LeonaBio, Inc. (CFO and Chief Business Officer · May 18, 2023 – Sep 3, 2024 · Past); Cyteir Therapeutics Inc (Chief Business Officer · Jun 17, 2021 – Feb 22, 2022 · Past); Synlogic Inc (Chief Operating Officer · Oct 9, 2017 – Mar 14, 2018 · Past) | Director · Since at least Oct 7, 2025 |
| Arthur Golden Other companies: Emerson Electric Company (Director · Feb 7, 2023 – Nov 8, 2023 · Past) | Director · Since at least Oct 7, 2025 |
| Andrew Scott | Vice President of Corporate Communications · Nov 4, 2025 – Nov 5, 2026 · Past |
| Bradley Burnam | Chief Executive Officer, Director · Since at least May 28, 2026 |
| Kent Kester | Director · Since at least Oct 7, 2025 |
| Martin Dewhurst | Director · Since at least Mar 31, 2026 |
| Muhammad Zubair | Controller · Since at least Nov 4, 2026 |
| Neil Ghodadra | Chief Medical Officer, Board Director · Since at least Nov 4, 2026 |
| Robert R. Redfield | Chief Scientific Officer · Since at least Sep 9, 2026 |
| Sasha Damouni | Investor Relations / Media Contact · Since at least Sep 10, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Sasha Damouni Ellis | Corporate Communications & IR Lead · Since at least Jul 6, 2026 |
| Stephen M. Hahn | Executive Clinical and Regulatory Lead · Since at least Aug 12, 2026 |
| Zuraiz Chaudhary | Chief Accounting Officer, VP Finance · Since at least Oct 7, 2025 |
Log in to ask 6ix AI your own questions about Turn Therapeutics Inc.